Social Media Ideas for Pfizer

Pfizer furthers pneumococcal efforts, remains ‘comfortable’ taking on emerging threats: vaccine chief

After decades of developing vaccines to shield babies and adults from Streptococcus pneumonia infections, Pfizer is now taking another leap forward in its efforts to protect agains...

China surpassing Europe in Drug Innovation and Development, Pfizer Inc. (PFE) Executive says

<![CDATA[Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI]]>

China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn

Pfizer: The AI Hedge That Pays You To Stay Defensive

Pfizer Inc. (PFE): A Top Dividend Stock to Buy According to Hedge Funds amid Ibrance FDA Milestone

Pfizer CFO to step down; Denali sells a regulatory fast-pass

A search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GS...

China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

China’s Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes. The Hon...

Pfizer, Innovent strike $10B cancer drug deal

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead

The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations.

Pfizer (PFE) Stock Price Forecast: 2026, 2027, 2028–2030 and Beyond

Pfizer (#PFE) stocks have garnered considerable attention from investors thanks to their promising upside potential and highly active market conditions. Amid global economic volati...

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions it to leverage China’s...

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

The drugmaker aims for berobenatide to be the first monthly GLP-1 weight-loss injection, distinguishing it from blockbuster drugs like Wegovy and Eli Lilly’s Zepbound

A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five months to forge, but not without undergoing some stress...

Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech

Sanofi's pharmaceutical and therapeutics subsidiaries say the COVID-19 vaccines that have netted Pfizer and Moderna billions of dollars infringe their patents covering mRNA technol...

Fed. Circ. Backs Pfizer Win In Paxlovid Patent Dispute

The Federal Circuit on Tuesday refused to revive a patent that Pfizer was accused of infringing through its blockbuster Paxlovid COVID-19 treatment, rejecting the patent owner's ar...

Pfizer Reaches Tentative Settlement in Depo-Provera Cases, Bellwether Trial Vacated

U.S. District Judge M. Casey Rodgers, in the Northern District of Florida, postponed her expert ruling this month due to a settlement reached between Pfizer and lead counsel in the...

<![CDATA[FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010 ]]>

BNT162b2 Early Vaccine Effective Against COVID-19 Visits

In a pivotal advancement in the ongoing battle against the COVID-19 pandemic, a recent study published in Nature Communications has illuminated the early effectiveness of the BNT16...

Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy?

These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.

Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.

Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing

Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech in...

The Most Important Healthcare Stock You're Not Watching

Down more than 50% from its 2021 highs, this pharmaceutical giant has been forgotten by Wall Street.

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive]]>